Cryoport, Inc. (NASDAQ:CYRX - Free Report) - Research analysts at Roth Capital issued their FY2026 earnings per share (EPS) estimates for Cryoport in a research report issued on Wednesday, March 5th. Roth Capital analyst R. Baldry anticipates that the company will earn ($1.23) per share for the year. The consensus estimate for Cryoport's current full-year earnings is ($0.99) per share.
A number of other equities research analysts also recently weighed in on CYRX. Guggenheim initiated coverage on Cryoport in a report on Thursday, December 19th. They issued a "buy" rating and a $11.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price target on shares of Cryoport in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $12.29.
Get Our Latest Analysis on CYRX
Cryoport Price Performance
Shares of CYRX stock traded down $0.43 during trading hours on Thursday, reaching $6.23. The company's stock had a trading volume of 386,284 shares, compared to its average volume of 315,400. The firm's 50 day simple moving average is $7.25 and its 200-day simple moving average is $7.57. The company has a market capitalization of $307.96 million, a price-to-earnings ratio of -1.84 and a beta of 1.67. Cryoport has a fifty-two week low of $4.58 and a fifty-two week high of $20.10. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48.
Cryoport (NASDAQ:CYRX - Get Free Report) last issued its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.09). The business had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same period in the prior year, the business posted ($0.29) EPS.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Bullseye Asset Management LLC lifted its stake in shares of Cryoport by 58.7% in the 3rd quarter. Bullseye Asset Management LLC now owns 214,264 shares of the company's stock valued at $1,737,000 after acquiring an additional 79,244 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Cryoport during the 3rd quarter worth $3,405,000. Barclays PLC raised its position in Cryoport by 272.9% during the 3rd quarter. Barclays PLC now owns 81,417 shares of the company's stock worth $660,000 after purchasing an additional 59,582 shares during the last quarter. SG Americas Securities LLC raised its position in Cryoport by 44.8% during the 4th quarter. SG Americas Securities LLC now owns 146,789 shares of the company's stock worth $1,142,000 after purchasing an additional 45,430 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Cryoport by 1,464.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 305,237 shares of the company's stock worth $2,475,000 after purchasing an additional 285,726 shares during the last quarter. 92.90% of the stock is currently owned by institutional investors.
About Cryoport
(
Get Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Featured Stories
Before you consider Cryoport, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.
While Cryoport currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
